Eosinophilic Esophagitis Drug Market

Eosinophilic esophagitis (EoE, also spelled eosinophilic oesophagitis), also known as allergic oesophagitis, is an allergic inflammatory condition of the esophagus that involves eosinophils, a type of white blood cell. Symptoms are swallowing difficulty, food impaction, vomiting, and heartburn.

Eosinophilic esophagitis was first described in children but also occurs in adults. The condition is not well understood, but food allergy may play a significant role. The treatment may consist of removal of known or suspected triggers and medication to suppress the immune response.

Eosinophilic Esophagitis Drug Market studies the eosinophilic esophagitis drug market.
Eosinophilic Esophagitis Drug Market contains market size and forecasts of Eosinophilic Esophagitis Drug in global, including the following market information:
Global Eosinophilic Esophagitis Drug Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Eosinophilic Esophagitis Drug Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Eosinophilic Esophagitis Drug companies in 2021 (%)
The global Eosinophilic Esophagitis Drug market was valued at 133.6 million in 2021 and is projected to reach US$ 191.3 million by 2028, at a CAGR of 5.3% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Budesonide Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Eosinophilic Esophagitis Drug include AstraZeneca, GSK, Bayer, Adare Pharmaceuticals, DBV Technologies, Dr. Falk Pharma, Quorum Innovations, Takeda and Calypso, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Eosinophilic Esophagitis Drug manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Eosinophilic Esophagitis Drug Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Eosinophilic Esophagitis Drug Market Segment Percentages, by Type, 2021 (%)
Budesonide
Fluticasone
Others
Global Eosinophilic Esophagitis Drug Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Eosinophilic Esophagitis Drug Market Segment Percentages, by Application, 2021 (%)
Hospitals
Clinics
Drugstore
Global Eosinophilic Esophagitis Drug Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Eosinophilic Esophagitis Drug Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Eosinophilic Esophagitis Drug revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Eosinophilic Esophagitis Drug revenues share in global market, 2021 (%)
Key companies Eosinophilic Esophagitis Drug sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Eosinophilic Esophagitis Drug sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
AstraZeneca
GSK
Bayer
Adare Pharmaceuticals
DBV Technologies
Dr. Falk Pharma
Quorum Innovations
Takeda
Calypso
Celgene
Regeneron